MCA-205 Cells

MCA-205 is a murine fibrosarcoma cell line derived from C57BL/6 mice. It was originally established through methylcholanthrene-induced tumorigenesis, a classic chemical carcinogenesis approach widely used to generate transplantable tumor models in syngeneic mice. MCA-205 serves as an immunocompetent tumor model, meaning it can be implanted into immunocompetent C57BL/6 mice without rejection, making it highly suitable for preclinical studies of cancer immunotherapy and tumor immunology.

Biologically, MCA-205 tumors are classified as non-immunogenic or poorly immunogenic, a characteristic that reflects their low baseline antigenicity and reduced susceptibility to spontaneous immune-mediated rejection. This feature is particularly useful for evaluating the efficacy of checkpoint blockade therapies (such as anti-PD-1 or anti-CTLA-4) or tumor vaccines under conditions that mirror the immune-evasive nature of many human cancers. Despite their poor intrinsic immunogenicity, MCA-205 tumors can respond to immune modulation when combined with radiation therapy, oncolytic viruses, or TLR agonists, making them a versatile platform for combinatorial treatment testing.

MCA-205 cells grow rapidly both in vitro and in vivo, forming aggressive fibrosarcomas when injected subcutaneously. These tumors have a high degree of vascularization and support reproducible tumor growth kinetics, allowing for consistent measurement of tumor burden and treatment response. Due to their murine origin and syngeneicity with C57BL/6 mice, MCA-205 cells are not appropriate for human-specific assays but are indispensable for exploring immune mechanisms in a fully functional host immune system.